SGLT2 inhibitors should be prescribed to all patients with diabetes, regardless of whether or not they have a current or previous foot ulcer, unless they have contraindications such as type 1 diabetes or an instance of diabetic ketoacidosis in the last year. This evidence concerns the gene SLC5A2 and diabetes mellitus.